The Tillotts Executive Committee (EXEC) is responsible for the strategic direction of the Tillotts Group. They oversee the timely implementation of various strategic initiatives agreed with the Board of Directors. Day-to-day management of the company has been delegated to the Senior Management Committee (SMC). The EXEC acts as a bridge between the Board of Directors and operational management.
Learn more about each member here.
Thomas A. Tóth von Kiskér
Chief Executive Officer, Vice-Chairman of the Tillotts Board
Thomas A. Tóth von Kiskér has been with Tillotts for more than 25 years in various roles and positions.
Since January 2008, he has been the CEO of Tillotts.
Adrian Hill,
Chief Commercial Officer
Adrian Hill joined Tillotts in January 2019. He has more than 30 years experience in commercial activities including experience in global marketing from several companies including Sanofi, GSK and most recently Kyowa Kirin.
Johannes Spleiss
Chief Scientific Officer
Johannes Spleiss joined Tillotts in November 1998. He took on positions of increasing responsibility and is now leading R&D, Medical Affairs, Drug Safety and Regulatory Affairs. A chemist by training, he has 30 years of experience in the pharmaceutical industry.
Mirjam von Zedtwitz
Secretary of the EXEC
Mirjam von Zedtwitz joined Tillotts in July 2024. She is a German qualified attorney with more than 20 years of experience working as in-house counsel in the pharmaceutical, biotechnology and medical technology industry.
The Senior Management Committee, responsible for the operational activities at Tillotts, consists of seven experienced managers, with Harald Haubitz serving as the chair of the committee.
Moreover, they monitor the activities of the organisation to ensure they are in line with our company objectives and values.
Sandra Annani
Head of Business Initiatives
Sandra Annani joined Tillotts in July 1997 and has since held a variety of commercially focused roles, including actively contributing to the establishment of affiliates across Europe. With a background in Business Administration, she brings valuable expertise and long-standing experience to the company.
Jan Deresiewicz
Managing Director DACH & Nordics
Jan Deresiewicz joined Tillotts in January 2012. With more than 25 years of pharma experience, he has held Nordic, German and global sales and marketing positions in companies such as Bayer and AstraZeneca.
Harald Haubitz
Chairman of the SMC/Head of Technical Operations
Harald Haubitz joined Tillotts in January 2018. He is a pharmacist by training with over 25 years of experience in the pharmaceutical industry. Previously he held different management positions at Roche and was the COO of Acino for several years before he ran his own consultancy business.
Oliver Isch
Head of Finance
Oliver Isch joined Tillotts in 2016 as Senior Business Controller. In September 2024, he was promoted to Head of Finance. Prior to working for Tillotts, he worked in various industries as Controller and Risk Manager. He is a Chartered Expert in Financial and Managerial Accounting and Reporting and has 20 years of experience in this field.
Gabriella Schraner
Head of Human Resources
Gabriella Schraner joined Tillotts in 2013. In February 2016, she was promoted to Head of HR. She is a Human Resources expert by training with specialization in International HR with more than 10 years of experience. Prior to Tillotts, she mainly worked in the biotechnology industry.
Mirjam von Zedtwitz
General Counsel
Mirjam von Zedtwitz joined Tillotts in July 2024. She is a German qualified attorney with more than 20 years of experience working as in-house counsel in the pharmaceutical, biotechnology and medical technology industry.
Christian Weidenfeller
Head of Medical Affairs Anti-Infectives
Christian Weidenfeller joined Tillotts in April 2021. He holds a Ph.D. in Biochemistry and has 18 years of experience in the pharmaceutical industry, spanning research, preclinical and clinical development, and Medical Affairs. He has worked with companies such as Merck Serono, EMD Serono, Pfizer, Celgene, and Sunovion across various therapeutic areas.